Last quarter (Q4 2022), Cyclopharm Limited's total revenue was $―, a decrease of ― from the same quarter last year. In Q4, Cyclopharm Limited's net income was $―. See Cyclopharm Limited’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	$ ―	$ 23.22M	$ 17.70M	$ 14.68M	$ 14.08M	$ 13.40M
Cost of Revenue	$ ―	$ 7.44M	$ 5.04M	$ 3.96M	$ 2.91M	$ 2.97M
Gross Profit	$ ―	$ 15.78M	$ 12.66M	$ 10.71M	$ 11.17M	$ 10.44M
Operating Expense	$ ―	$ 23.41M	$ 19.61M	$ 19.20M	$ 17.43M	$ 13.20M
Operating Income	$ ―	$ -7.63M	$ -6.95M	$ -8.49M	$ -6.26M	$ -2.76M
Net Non Operating Interest Income Expense	$ ―	$ -156.19K	$ -85.36K	$ -203.45K	$ -254.75K	$ 77.28K
Other Income Expense	$ ―	$ 1.76M	$ 2.69M	$ 2.85M	$ 4.09M	$ 2.80M
Pretax Income	$ ―	$ -6.03M	$ -4.35M	$ -5.84M	$ -2.42M	$ 118.41K
Tax Provision	$ ―	$ 581.67K	$ 693.29K	$ 199.53K	$ 487.50K	$ 153.86K
Earnings From Equity Interest Net Of Tax	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Net Income Common Stockholders	$ ―	$ -6.61M	$ -5.04M	$ -6.04M	$ -2.91M	$ -35.46K
Basic EPS	$ ―	$ -0.07	$ -0.06	$ -0.08	$ -0.04	$ >-0.01
Diluted EPS	$ ―	$ -0.07	$ -0.06	$ -0.08	$ -0.04	$ >-0.01
Basic Average Shares	$ ―	$ 92.18M	$ 89.69M	$ 76.59M	$ 68.12M	$ 67.97M
Diluted Average Shares	$ ―	$ 92.18M	$ 89.69M	$ 76.59M	$ 68.12M	$ 67.97M
Dividend Per Share	$ ―	$ 0.01	$ 0.01	$ 0.01	$ 0.01	$ 0.01
Total Operating Income As Reported	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Reported Normalized Basic E P S	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Reported Normalized Diluted E P S	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Rent Expense Supplemental	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Total Expenses	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Net Income From Continuing And Discontinued Operation	$ ―	$ -6.61M	$ -5.04M	$ -6.04M	$ -2.91M	$ -35.46K
Normalized Income	$ ―	$ -6.61M	$ -5.04M	$ -6.04M	$ -2.91M	$ -35.46K
Interest Expense	$ ―	$ 67.43K	$ 16.52K	$ 18.21K	$ 46.87K	$ 26.13K
EBIT	$ ―	$ -5.96M	$ -4.33M	$ -5.83M	$ -2.38M	$ 144.54K
EBITDA	$ ―	$ -5.03M	$ -3.57M	$ -4.92M	$ -1.38M	$ 654.77K

Currency in USD

Cyclopharm Limited Earnings and Revenue History

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing